SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zhan, F. Articles by Shaughnessy, J. Search for Related Content PubMed PubMed Citation Articles by Zhan, F. Articles by Shaughnessy, J., Jr Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 March 2002, Vol. 99, No. 5, pp. 1745-1757 NEOPLASIA Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells Fenghuang Zhan, Johanna Hardin, Bob Kordsmeier, Klaus Bumm, Mingzhong Zheng, Erming Tian, Ralph Sanderson, Yang Yang, Carla Wilson, Maurizio Zangari, Elias Anaissie, Christopher Morris, Firas Muwalla, Frits van Rhee, Athanasios Fassas, John Crowley, Guido Tricot, Bart Barlogie, and John Shaughnessy Jr From the Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, or Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, and the Southwest Oncology Group, Fred Hutchinson Cancer Research Center, Seattle, WA. Bone marrow plasma cells (PCs) from 74 patients with newly diagnosed multiple myeloma (MM), 5 with monoclonal gammopathy of undetermined significance (MGUS), and 31 healthy volunteers (normal PCs) were purified by CD138+ selection. Gene expression of purified PCs and 7 MM cell lines were profiled using high-density oligonucleotide microarrays interrogating about 6800 genes. On hierarchical clustering analysis, normal and MM PCs were differentiated and 4 distinct subgroups of MM (MM1, MM2, MM3, and MM4) were identified. The expression pattern of MM1 was similar to normal PCs and MGUS, whereas MM4 was similar to MM cell lines. Clinical parameters linked to poor prognosis, abnormal karyotype (P = .002) and high serum 2-microglobulin levels (P = .0005), were most prevalent in MM4. Also, genes involved in DNA metabolism and cell cycle control were overexpressed in a comparison of MM1 and MM4. In addition, using 2 and Wilcoxon rank sum tests, 120 novel candidate disease genes were identified that discriminate normal and malignant PCs (P < .0001); many are involved in adhesion, apoptosis, cell cycle, drug resistance, growth arrest, oncogenesis, signaling, and transcription. A total of 156 genes, including FGFR3 and CCND1, exhibited highly elevated ("spiked") expression in at least 4 of the 74 MM cases (range, 4-25 spikes). Elevated expression of these 2 genes was caused by the translocation t(4;14)(p16;q32) or t(11;14)(q13;q32). Thus, novel candidate MM disease genes have been identified using gene expression profiling and this profiling has led to the development of a gene-based classification system for MM. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Kukreja, S. Radfar, B.-H. Sun, K. Insogna, and M. V. Dhodapkar Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease Blood, October 15, 2009; 114(16): 3413 - 3421. [Abstract] [Full Text] [PDF] H. Avet-Loiseau, C. Li, F. Magrangeas, W. Gouraud, C. Charbonnel, J.-L. Harousseau, M. Attal, G. Marit, C. Mathiot, T. Facon, et al. Prognostic Significance of Copy-Number Alterations in Multiple Myeloma J. Clin. Oncol., September 20, 2009; 27(27): 4585 - 4590. [Abstract] [Full Text] [PDF] T. B. Bartel, J. Haessler, T. L. Y. Brown, J. D. Shaughnessy Jr, F. van Rhee, E. Anaissie, T. Alpe, E. Angtuaco, R. Walker, J. Epstein, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma Blood, September 3, 2009; 114(10): 2068 - 2076. [Abstract] [Full Text] [PDF] A. Anguiano, S. A. Tuchman, C. Acharya, K. Salter, C. Gasparetto, F. Zhan, M. Dhodapkar, J. Nevins, B. Barlogie, J. D. Shaughnessy Jr, et al. Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma J. Clin. Oncol., September 1, 2009; 27(25): 4197 - 4203. [Abstract] [Full Text] [PDF] F. van Rhee, S. M. Szmania, M. Dillon, A. M. van Abbema, X. Li, M. K. Stone, T. K. Garg, J. Shi, A. M. Moreno-Bost, R. Yun, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma Mol. Cancer Ther., September 1, 2009; 8(9): 2616 - 2624. [Abstract] [Full Text] [PDF] A. Pennisi, W. Ling, X. Li, S. Khan, J. D. Shaughnessy Jr, B. Barlogie, and S. Yaccoby The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth Blood, August 27, 2009; 114(9): 1803 - 1812. [Abstract] [Full Text] [PDF] A. Hoering, J. Crowley, J. D Shaughnessy Jr, K. Hollmig, Y. Alsayed, J. Szymonifka, S. Waheed, B. Nair, F. van Rhee, E. Anaissie, et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols Blood, August 13, 2009; 114(7): 1299 - 1305. [Abstract] [Full Text] [PDF] S. Wang, G. Tricot, L. Shi, W. Xiong, Z. Zeng, H. Xu, M. Zangari, B. Barlogie, J. D. Shaughnessy Jr, and F. Zhan RAR{alpha}2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma Blood, July 16, 2009; 114(3): 600 - 607. [Abstract] [Full Text] [PDF] M. Condomines, D. Hose, T. Reme, G. Requirand, M. Hundemer, M. Schoenhals, H. Goldschmidt, and B. Klein Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma J. Immunol., July 15, 2009; 183(2): 832 - 840. [Abstract] [Full Text] [PDF] W. J. Chng, E. D. Remstein, R. Fonseca, P. L. Bergsagel, J. A. Vrana, P. J. Kurtin, and A. Dogan Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications Blood, January 15, 2009; 113(3): 635 - 645. [Abstract] [Full Text] [PDF] W. Xiong, X. Wu, S. Starnes, S. K. Johnson, J. Haessler, S. Wang, L. Chen, B. Barlogie, J. D. Shaughnessy Jr, and F. Zhan An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma Blood, November 15, 2008; 112(10): 4235 - 4246. [Abstract] [Full Text] [PDF] S. Y. Kristinsson, T. R. Fears, G. Gridley, I. Turesson, U.-H. Mellqvist, M. Bjorkholm, and O. Landgren Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma Blood, November 1, 2008; 112(9): 3582 - 3586. [Abstract] [Full Text] [PDF] F. Pichiorri, S.-S. Suh, M. Ladetto, M. Kuehl, T. Palumbo, D. Drandi, C. Taccioli, N. Zanesi, H. Alder, J. P. Hagan, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis PNAS, September 2, 2008; 105(35): 12885 - 12890. [Abstract] [Full Text] [PDF] B. Burington, B. Barlogie, F. Zhan, J. Crowley, and J. D. Shaughnessy Jr. Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma Clin. Cancer Res., August 1, 2008; 14(15): 4821 - 4829. [Abstract] [Full Text] [PDF] Y.-W. Qiang, J. D. Shaughnessy Jr, and S. Yaccoby Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth Blood, July 15, 2008; 112(2): 374 - 382. [Abstract] [Full Text] [PDF] X. Li, A. Pennisi, and S. Yaccoby Role of decorin in the antimyeloma effects of osteoblasts Blood, July 1, 2008; 112(1): 159 - 168. [Abstract] [Full Text] [PDF] P. M Voorhees, E C. Dees, B. O'Neil, and R. Z Orlowski The Proteasome as a Target for Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 153 - 170. [Abstract] [Full Text] [PDF] K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications Clin. Cancer Res., December 15, 2007; 13(24): 7289 - 7295. [Abstract] [Full Text] [PDF] S. Colla, S. Tagliaferri, F. Morandi, P. Lunghi, G. Donofrio, D. Martorana, C. Mancini, M. Lazzaretti, L. Mazzera, L. Ravanetti, et al. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 {alpha} (HIF-1{alpha}) activity: involvement in myeloma-induced angiogenesis Blood, December 15, 2007; 110(13): 4464 - 4475. [Abstract] [Full Text] [PDF] J. Haessler, J. D. Shaughnessy Jr., F. Zhan, J. Crowley, J. Epstein, F. van Rhee, E. Anaissie, M. Pineda-Roman, M. Zangari, K. Hollmig, et al. Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling Clin. Cancer Res., December 1, 2007; 13(23): 7073 - 7079. [Abstract] [Full Text] [PDF] C. M. Stellrecht, C. J. Phillip, F. Cervantes-Gomez, and V. Gandhi Multiple Myeloma Cell Killing by Depletion of the MET Receptor Tyrosine Kinase Cancer Res., October 15, 2007; 67(20): 9913 - 9920. [Abstract] [Full Text] [PDF] Y. Yang, V. MacLeod, Y. Dai, Y. Khotskaya-Sample, Z. Shriver, G. Venkataraman, R. Sasisekharan, A. Naggi, G. Torri, B. Casu, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy Blood, September 15, 2007; 110(6): 2041 - 2048. [Abstract] [Full Text] [PDF] F. Zhan, S. Colla, X. Wu, B. Chen, J. P. Stewart, W. M. Kuehl, B. Barlogie, and J. D. Shaughnessy Jr CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms Blood, June 1, 2007; 109(11): 4995 - 5001. [Abstract] [Full Text] [PDF] K. L.M. Boylan, M. A. Gosse, S. E. Staggs, S. Janz, S. Grindle, G. S. Kansas, and B. G. Van Ness A Transgenic Mouse Model of Plasma Cell Malignancy Shows Phenotypic, Cytogenetic, and Gene Expression Heterogeneity Similar to Human Multiple Myeloma Cancer Res., May 1, 2007; 67(9): 4069 - 4078. [Abstract] [Full Text] [PDF] E. M. Hurt, S. B. Thomas, B. Peng, and W. L. Farrar Integrated molecular profiling of SOD2 expression in multiple myeloma Blood, May 1, 2007; 109(9): 3953 - 3962. [Abstract] [Full Text] [PDF] G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. J. Chng, S. Roels, E. Koenig, A. Fergus, Y. Huang, P. Richardson, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib Blood, April 15, 2007; 109(8): 3177 - 3188. [Abstract] [Full Text] [PDF] H. Avet-Loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, S. Leyvraz, M. Michallet, I. Yakoub-Agha, L. Garderet, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Blood, April 15, 2007; 109(8): 3489 - 3495. [Abstract] [Full Text] [PDF] T. Standal, N. Abildgaard, U.-M. Fagerli, B. Stordal, O. Hjertner, M. Borset, and A. Sundan HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma Blood, April 1, 2007; 109(7): 3024 - 3030. [Abstract] [Full Text] [PDF] J. D. Shaughnessy Jr, F. Zhan, B. E. Burington, Y. Huang, S. Colla, I. Hanamura, J. P. Stewart, B. Kordsmeier, C. Randolph, D. R. Williams, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 Blood, March 15, 2007; 109(6): 2276 - 2284. [Abstract] [Full Text] [PDF] D. L. Gold, K. R. Coombes, J. Wang, and B. Mallick Enrichment analysis in high-throughput genomics--accounting for dependency in the NULL Brief Bioinform, March 1, 2007; 8(2): 71 - 77. [Abstract] [Full Text] [PDF] S. H. Cheng, M. H. L. Ng, K. M. Lau, H. S. Y. Liu, J. C. W. Chan, A. B. Y. Hui, K. W. Lo, H. Jiang, J. Hou, R. W. Chu, et al. 4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4 Blood, March 1, 2007; 109(5): 2089 - 2099. [Abstract] [Full Text] [PDF] S. Yaccoby, W. Ling, F. Zhan, R. Walker, B. Barlogie, and J. D. Shaughnessy Jr Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo Blood, March 1, 2007; 109(5): 2106 - 2111. [Abstract] [Full Text] [PDF] F. Zhan, B. Barlogie, V. Arzoumanian, Y. Huang, D. R. Williams, K. Hollmig, M. Pineda-Roman, G. Tricot, F. van Rhee, M. Zangari, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis Blood, February 15, 2007; 109(4): 1692 - 1700. [Abstract] [Full Text] [PDF] L. Agnelli, S. Bicciato, S. Fabris, L. Baldini, F. Morabito, D. Intini, D. Verdelli, A. Callegaro, F. Bertoni, G. Lambertenghi-Deliliers, et al. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma Haematologica, January 1, 2007; 92(1): 56 - 65. [Abstract] [Full Text] [PDF] P. G. Richardson, T. Hideshima, and K. C. Anderson Plasma cell dyscrasias ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327. [Full Text] [PDF] J. Blade Monoclonal Gammopathy of Undetermined Significance N. Engl. J. Med., December 28, 2006; 355(26): 2765 - 2770. [Full Text] [PDF] W. J. Chng, R. F. Schop, T. Price-Troska, I. Ghobrial, N. Kay, D. F. Jelinek, M. A. Gertz, A. Dispenzieri, M. Lacy, R. A. Kyle, et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma Blood, October 15, 2006; 108(8): 2755 - 2763. [Abstract] [Full Text] [PDF] F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al. The molecular classification of multiple myeloma Blood, September 15, 2006; 108(6): 2020 - 2028. [Abstract] [Full Text] [PDF] I. Hanamura, J. P. Stewart, Y. Huang, F. Zhan, M. Santra, J. R. Sawyer, K. Hollmig, M. Zangarri, M. Pineda-Roman, F. van Rhee, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation Blood, September 1, 2006; 108(5): 1724 - 1732. [Abstract] [Full Text] [PDF] G. Bisping, M. Kropff, D. Wenning, B. Dreyer, S. Bessonov, F. Hilberg, G. J. Roth, G. Munzert, M. Stefanic, M. Stelljes, et al. Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups Blood, March 1, 2006; 107(5): 2079 - 2089. [Abstract] [Full Text] [PDF] S. Ely, M. Di Liberto, R. Niesvizky, L. B. Baughn, H. J. Cho, E. N. Hatada, D. M. Knowles, J. Lane, and S. Chen-Kiang Mutually Exclusive Cyclin-Dependent Kinase 4/Cyclin D1 and Cyclin-Dependent Kinase 6/Cyclin D2 Pairing Inactivates Retinoblastoma Protein and Promotes Cell Cycle Dysregulation in Multiple Myeloma Cancer Res., December 15, 2005; 65(24): 11345 - 11353. [Abstract] [Full Text] [PDF] Y. Dai, Y. Yang, V. MacLeod, X. Yue, A. C. Rapraeger, Z. Shriver, G. Venkataraman, R. Sasisekharan, and R. D. Sanderson HSulf-1 and HSulf-2 Are Potent Inhibitors of Myeloma Tumor Growth in Vivo J. Biol. Chem., December 2, 2005; 280(48): 40066 - 40073. [Abstract] [Full Text] [PDF] K. Boylan, M. A. Kvitrud, and B. G. Van Ness A Trangenic Mouse Model of Plasma Cell Malignancy Shows Cytogenetic and Gene Expression Profiles Similar to Human Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 619 - 619. [Abstract] S. A. Tomlins, D. R. Rhodes, S. Perner, S. M. Dhanasekaran, R. Mehra, X.-W. Sun, S. Varambally, X. Cao, J. Tchinda, R. Kuefer, et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer Science, October 28, 2005; 310(5748): 644 - 648. [Abstract] [Full Text] [PDF] L. Agnelli, S. Bicciato, M. Mattioli, S. Fabris, D. Intini, D. Verdelli, L. Baldini, F. Morabito, V. Callea, L. Lombardi, et al. Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations J. Clin. Oncol., October 10, 2005; 23(29): 7296 - 7306. [Abstract] [Full Text] [PDF] W. J. Chng, S. A. Van Wier, G. J. Ahmann, J. M. Winkler, S. M. Jalal, P. L. Bergsagel, M. Chesi, M. C. Trendle, M. M. Oken, E. Blood, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS Blood, September 15, 2005; 106(6): 2156 - 2161. [Abstract] [Full Text] [PDF] A. K. Stewart and R. Fonseca Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling J. Clin. Oncol., September 10, 2005; 23(26): 6339 - 6344. [Abstract] [Full Text] [PDF] E. P. M. Tjin, R. J. Bende, P. W. B. Derksen, A.-P. van Huijstee, H. Kataoka, M. Spaargaren, and S. T. Pals Follicular Dendritic Cells Catalyze Hepatocyte Growth Factor (HGF) Activation in the Germinal Center Microenvironment by Secreting the Serine Protease HGF Activator J. Immunol., September 1, 2005; 175(5): 2807 - 2813. [Abstract] [Full Text] [PDF] Y.-W. Qiang, K. Walsh, L. Yao, N. Kedei, P. M. Blumberg, J. S. Rubin, J. Shaughnessy Jr, and S. Rudikoff Wnts induce migration and invasion of myeloma plasma cells Blood, September 1, 2005; 106(5): 1786 - 1793. [Abstract] [Full Text] [PDF] S. Girlanda, C. Fortis, D. Belloni, E. Ferrero, P. Ticozzi, C. Sciorati, M. Tresoldi, A. Vicari, T. Spies, V. Groh, et al. MICA Expressed by Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Plasma Cells Costimulates Pamidronate-Activated {gamma}{delta} Lymphocytes Cancer Res., August 15, 2005; 65(16): 7502 - 7508. [Abstract] [Full Text] [PDF] J. Moreaux, F. W. Cremer, T. Reme, M. Raab, K. Mahtouk, P. Kaukel, V. Pantesco, J. De Vos, E. Jourdan, A. Jauch, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature Blood, August 1, 2005; 106(3): 1021 - 1030. [Abstract] [Full Text] [PDF] P. L. Bergsagel, W. M. Kuehl, F. Zhan, J. Sawyer, B. Barlogie, and J. Shaughnessy Jr Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma Blood, July 1, 2005; 106(1): 296 - 303. [Abstract] [Full Text] [PDF] D. R. Hodge, B. Peng, J. C. Cherry, E. M. Hurt, S. D. Fox, J. A. Kelley, D. J. Munroe, and W. L. Farrar Interleukin 6 Supports the Maintenance of p53 Tumor Suppressor Gene Promoter Methylation Cancer Res., June 1, 2005; 65(11): 4673 - 4682. [Abstract] [Full Text] [PDF] F. van Rhee, S. M. Szmania, F. Zhan, S. K. Gupta, M. Pomtree, P. Lin, R. B. Batchu, A. Moreno, G. Spagnoli, J. Shaughnessy, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses Blood, May 15, 2005; 105(10): 3939 - 3944. [Abstract] [Full Text] [PDF] L. Guedez, A. Martinez, S. Zhao, A. Vivero, S. Pittaluga, M. Stetler-Stevenson, M. Raffeld, and W. G. Stetler-Stevenson Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors Blood, February 15, 2005; 105(4): 1660 - 1668. [Abstract] [Full Text] [PDF] R. S. Abraham, K. V. Ballman, A. Dispenzieri, D. E. Grill, M. K. Manske, T. L. Price-Troska, N. G. Paz, M. A. Gertz, and R. Fonseca Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis Blood, January 15, 2005; 105(2): 794 - 803. [Abstract] [Full Text] [PDF] H. Hov, R. U. Holt, T. B. Ro, U.-M. Fagerli, H. Hjorth-Hansen, V. Baykov, J. G. Christensen, A. Waage, A. Sundan, and M. Borset A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells Clin. Cancer Res., October 1, 2004; 10(19): 6686 - 6694. [Abstract] [Full Text] [PDF] A. M. Dring, F. E. Davies, J. A. L. Fenton, P. L. Roddam, K. Scott, D. Gonzalez, S. Rollinson, A. C. Rawstron, K. S. Rees-Unwin, C. Li, et al. A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in Myeloma Clin. Cancer Res., September 1, 2004; 10(17): 5692 - 5701. [Abstract] [Full Text] [PDF] C. A. Maxwell, E. Rasmussen, F. Zhan, J. J. Keats, S. Adamia, E. Strachan, M. Crainie, R. Walker, A. R. Belch, L. M. Pilarski, et al. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma Blood, August 15, 2004; 104(4): 1151 - 1158. [Abstract] [Full Text] [PDF] T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson Advances in biology of multiple myeloma: clinical applications Blood, August 1, 2004; 104(3): 607 - 618. [Abstract] [Full Text] [PDF] S. Trudel, S. Ely, Y. Farooqi, M. Affer, D. F. Robbiani, M. Chesi, and P. L. Bergsagel Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma Blood, May 1, 2004; 103(9): 3521 - 3528. [Abstract] [Full Text] [PDF] P. W. B. Derksen, E. Tjin, H. P. Meijer, M. D. Klok, H. D. Mac Gillavry, M. H. J. van Oers, H. M. Lokhorst, A. C. Bloem, H. Clevers, R. Nusse, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells PNAS, April 20, 2004; 101(16): 6122 - 6127. [Abstract] [Full Text] [PDF] N. C. Munshi, T. Hideshima, D. Carrasco, M. Shammas, D. Auclair, F. Davies, N. Mitsiades, C. Mitsiades, R. S. Kim, C. Li, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples Blood, March 1, 2004; 103(5): 1799 - 1806. [Abstract] [Full Text] [PDF] R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al. Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report Cancer Res., February 15, 2004; 64(4): 1546 - 1558. [Abstract] [Full Text] [PDF] M. Xiong, J. Li, and X. Fang Identification of Genetic Networks Genetics, February 1, 2004; 166(2): 1037 - 1052. [Abstract] [Full Text] [PDF] J.-L. Harousseau, J. Shaughnessy Jr., and P. Richardson Multiple Myeloma Hematology, January 1, 2004; 2004(1): 237 - 256. [Abstract] [Full Text] [PDF] B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley Treatment of multiple myeloma Blood, January 1, 2004; 103(1): 20 - 32. [Abstract] [Full Text] [PDF] E. S. Wang, K. Wu, A. C. Chin, S. Chen-Kiang, K. Pongracz, S. Gryaznov, and M. A. S. Moore Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma Blood, January 1, 2004; 103(1): 258 - 266. [Abstract] [Full Text] [PDF] E. Tian, F. Zhan, R. Walker, E. Rasmussen, Y. Ma, B. Barlogie, and J. D. Shaughnessy Jr. The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma N. Engl. J. Med., December 25, 2003; 349(26): 2483 - 2494. [Abstract] [Full Text] [PDF] T. Kelly, H.-Q. Miao, Y. Yang, E. Navarro, P. Kussie, Y. Huang, V. MacLeod, J. Casciano, L. Joseph, F. Zhan, et al. High Heparanase Activity in Multiple Myeloma Is Associated with Elevated Microvessel Density Cancer Res., December 15, 2003; 63(24): 8749 - 8756. [Abstract] [Full Text] [PDF] P. M. Voorhees, E. C. Dees, B. O'Neil, and R. Z. Orlowski The Proteasome as a Target for Cancer Therapy Clin. Cancer Res., December 15, 2003; 9(17): 6316 - 6325. [Abstract] [Full Text] [PDF] F. E. Davies, A. M. Dring, C. Li, A. C. Rawstron, M. A. Shammas, S. M. O'Connor, J. A.L. Fenton, T. Hideshima, D. Chauhan, I. T. Tai, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis Blood, December 15, 2003; 102(13): 4504 - 4511. [Abstract] [Full Text] [PDF] M. V. Dhodapkar, J. Krasovsky, K. Osman, and M. D. Geller Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy J. Exp. Med., December 1, 2003; 198(11): 1753 - 1757. [Abstract] [Full Text] [PDF] J. McCafferty-Grad, N. J. Bahlis, N. Krett, T. M. Aguilar, I. Reis, K. P. Lee, and L. H. Boise Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells Mol. Cancer Ther., November 1, 2003; 2(11): 1155 - 1164. [Abstract] [Full Text] [PDF] N. Ochiai, R. Uchida, S.-i. Fuchida, A. Okano, M. Okamoto, E. Ashihara, T. Inaba, N. Fujita, H. Matsubara, and C. Shimazaki Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro Blood, November 1, 2003; 102(9): 3349 - 3353. [Abstract] [Full Text] [PDF] P. A. Croonquist, M. A. Linden, F. Zhao, and B. G. Van Ness Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells Blood, October 1, 2003; 102(7): 2581 - 2592. [Abstract] [Full Text] [PDF] J. Shaughnessy Jr Primer on Medical Genomics Part IX: Scientific and Clinical Applications of DNA Microarrays--Multiple Myeloma as a Disease Model Mayo Clin. Proc., September 1, 2003; 78(9): 1098 - 1109. [Abstract] [PDF] O. N. Onwuazor, X.-Y. Wen, D.-Y. Wang, L. Zhuang, E. Masih-Khan, J. Claudio, B. Barlogie, J. D. Shaughnessy Jr, and A. K. Stewart Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients Blood, July 15, 2003; 102(2): 772 - 773. [Full Text] [PDF] K. Tarte, F. Zhan, J. De Vos, B. Klein, and J. Shaughnessy Jr Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation Blood, July 15, 2003; 102(2): 592 - 600. [Abstract] [Full Text] [PDF] M. V. Dhodapkar, M. D. Geller, D. H. Chang, K. Shimizu, S.-I. Fujii, K. M. Dhodapkar, and J. Krasovsky A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma J. Exp. Med., June 16, 2003; 197(12): 1667 - 1676. [Abstract] [Full Text] [PDF] K.-D. Wu, L. M. Orme, J. Shaughnessy Jr, J. Jacobson, B. Barlogie, and M. A. S. Moore Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival Blood, June 15, 2003; 101(12): 4982 - 4989. [Abstract] [Full Text] [PDF] F. Magrangeas, V. Nasser, H. Avet-Loiseau, B. Loriod, O. Decaux, S. Granjeaud, F. Bertucci, D. Birnbaum, C. Nguyen, J.-L. Harousseau, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease Blood, June 15, 2003; 101(12): 4998 - 5006. [Abstract] [Full Text] [PDF] J. Shaughnessy, J. Jacobson, J. Sawyer, J. McCoy, A. Fassas, F. Zhan, K. Bumm, J. Epstein, E. Anaissie, S. Jagannath, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression Blood, May 15, 2003; 101(10): 3849 - 3856. [Abstract] [Full Text] [PDF] G. H. Underhill, D. George, E. G. Bremer, and G. S. Kansas Gene expression profiling reveals a highly specialized genetic program of plasma cells Blood, May 15, 2003; 101(10): 4013 - 4021. [Abstract] [Full Text] [PDF] D. Chauhan, G. Li, D. Auclair, T. Hideshima, P. Richardson, K. Podar, N. Mitsiades, C. Mitsiades, C. Li, R. S. Kim, et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays Blood, May 1, 2003; 101(9): 3606 - 3614. [Abstract] [Full Text] [PDF] M. Santra, F. Zhan, E. Tian, B. Barlogie, and J. Shaughnessy Jr A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript Blood, March 15, 2003; 101(6): 2374 - 2376. [Abstract] [Full Text] [PDF] P. L. Bergsagel Prognostic Factors in Multiple Myeloma: It's in the Genes Clin. Cancer Res., February 1, 2003; 9(2): 533 - 534. [Full Text] [PDF] C. Milazzo, V. L. Reichardt, M. R. Muller, F. Grunebach, and P. Brossart Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA Blood, February 1, 2003; 101(3): 977 - 982. [Abstract] [Full Text] [PDF] F. Zhan, E. Tian, K. Bumm, R. Smith, B. Barlogie, and J. Shaughnessy Jr Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development Blood, February 1, 2003; 101(3): 1128 - 1140. [Abstract] [Full Text] [PDF] S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot Advances in Biology and Therapy of Multiple Myeloma Hematology, January 1, 2003; 2003(1): 248 - 278. [Abstract] [Full Text] [PDF] K. C. Anderson Multiple Myeloma: How Far Have We Come? Mayo Clin. Proc., January 1, 2003; 78(1): 15 - 17. [PDF] G Pratt Molecular aspects of multiple myeloma Mol. Pathol., October 1, 2002; 55(5): 273 - 283. [Abstract] [Full Text] [PDF] M. S. Bendre, D. Gaddy-Kurten, T. Mon-Foote, N. S. Akel, R. A. Skinner, R. W. Nicholas, and L. J. Suva Expression of Interleukin 8 and not Parathyroid Hormone-related Protein by Human Breast Cancer Cells Correlates with Bone Metastasis in Vivo Cancer Res., October 1, 2002; 62(19): 5571 - 5579. [Abstract] [Full Text] [PDF] J. O. Claudio, E. Masih-Khan, H. Tang, J. Goncalves, M. Voralia, Z. H. Li, V. Nadeem, E. Cukerman, O. Francisco-Pabalan, C. C. Liew, et al. A molecular compendium of genes expressed in multiple myeloma Blood, August 28, 2002; 100(6): 2175 - 2186. [Abstract] [Full Text] [PDF] K. Tarte, J. De Vos, T. Thykjaer, F. Zhan, G. Fiol, V. Costes, T. Reme, E. Legouffe, J.-F. Rossi, J. Shaughnessy Jr, et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts Blood, July 30, 2002; 100(4): 1113 - 1122. [Abstract] [Full Text] [PDF] M. Akiyama, T. Hideshima, T. Hayashi, Y.-T. Tai, C. S. Mitsiades, N. Mitsiades, D. Chauhan, P. Richardson, N. C. Munshi, and K. C. Anderson Cytokines Modulate Telomerase Activity in a Human Multiple Myeloma Cell Line Cancer Res., July 1, 2002; 62(13): 3876 - 3882. [Abstract] [Full Text] [PDF] K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman Multiple Myeloma Hematology, January 1, 2002; 2002(1): 214 - 240. [Abstract] [Full Text]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020